These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 25395410)
1. Understanding the functions of endogenous and exogenous tissue-type plasminogen activator during stroke. Docagne F; Parcq J; Lijnen R; Ali C; Vivien D Stroke; 2015 Jan; 46(1):314-20. PubMed ID: 25395410 [No Abstract] [Full Text] [Related]
2. [Thrombolytic therapy for acute ischemic stroke]. Mori E Nihon Rinsho; 2006 Nov; 64 Suppl 8():33-7. PubMed ID: 17469531 [No Abstract] [Full Text] [Related]
3. Plasminogen activation and thrombolysis for ischemic stroke. Medcalf RL; Davis SM Int J Stroke; 2012 Jul; 7(5):419-25. PubMed ID: 22463085 [TBL] [Abstract][Full Text] [Related]
4. Tissue plasminogen activator approved for stroke. Barber A; Gommans J N Z Med J; 2005 May; 118(1214):U1432. PubMed ID: 15886728 [No Abstract] [Full Text] [Related]
5. [Thrombolytic therapy with tPA for the treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke study]. Di Pasquale G Ital Heart J Suppl; 2000 Jul; 1(7):947-8. PubMed ID: 10935744 [No Abstract] [Full Text] [Related]
6. Predictors of lack of improvement after thrombolytic stroke therapy. Pastewski A; Kupfer Y; Tessler S JAMA; 2005 Jan; 293(4):421; author reply 421. PubMed ID: 15671423 [No Abstract] [Full Text] [Related]
7. The 4.5-hour time window for intravenous thrombolysis with intravenous tissue-type plasminogen activator is not firmly established. Wechsler LR Stroke; 2014 Mar; 45(3):914-5. PubMed ID: 24526061 [No Abstract] [Full Text] [Related]
8. 4.5-hour time window for intravenous thrombolysis with recombinant tissue-type plasminogen activator is established firmly. Schellinger PD; Köhrmann M Stroke; 2014 Mar; 45(3):912-3. PubMed ID: 24526060 [No Abstract] [Full Text] [Related]
9. 4.5 hours: the new time window for tissue plasminogen activator in stroke. Davis SM; Donnan GA Stroke; 2009 Jun; 40(6):2266-7. PubMed ID: 19407232 [No Abstract] [Full Text] [Related]
10. Intravenous thrombolytic therapy for acute ischemic stroke. Wechsler LR N Engl J Med; 2011 Jun; 364(22):2138-46. PubMed ID: 21631326 [No Abstract] [Full Text] [Related]
11. Thrombolytic therapy for acute ischemic stroke: risks vs benefits. Lindbloom EJ J Fam Pract; 2003 Oct; 52(10):757, 761. PubMed ID: 14529595 [No Abstract] [Full Text] [Related]
12. When is enough enough? Donnan GA; Davis SM Stroke; 2001 Nov; 32(11):2710-1. PubMed ID: 11692042 [No Abstract] [Full Text] [Related]
13. Further randomized controlled trials of tissue plasminogen activator within 3 hours are required. Lindley RI Stroke; 2001 Nov; 32(11):2708-9. PubMed ID: 11692040 [No Abstract] [Full Text] [Related]
14. Litigation regarding tPA and stroke. Pilcher CA Ann Emerg Med; 2009 Mar; 53(3):404; author reply 404-5. PubMed ID: 19231673 [No Abstract] [Full Text] [Related]
15. IV and IA thrombolytic stroke strategies are complementary. Donnan GA; Davis SM Stroke; 2009 Jul; 40(7):2615. PubMed ID: 19443794 [No Abstract] [Full Text] [Related]
16. Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator-related hemorrhagic transformation. Montaner J Stroke; 2008 Jan; 39(1):e6. PubMed ID: 18048844 [No Abstract] [Full Text] [Related]